Integrated efficacy and safety analysis of GT1-6 treatment-naive, non-cirrhotic and compensated cirrhotic patients who received 8 weeks of glecaprevir/pibrentasvir
HEPATOLOGY(2020)
关键词
non-cirrhotic patients,treatment-naive
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要